. Author manuscript; available in PMC: 2009 May 1.

Published in final edited form as: Am J Cardiol. 2008 May 28;102(3):321–325. doi: 10.1016/j.amjcard.2008.03.057

Table 4.

Effect of atorvastatin on biomarkers of oxidative stress in subjects with metabolic syndrome

Variable			Atorvastatin
	Placebo		10 mg/d		80 mg/d
	Baseline	Week 12	Baseline	Week 12	Baseline	Week 12
Oxidized LDL (IU/L)	48 ± 15	51 ± 12	56 ± 19	42 ± 17^*^†	55 ± 22	34 ± 20^‡^§
Urinary nitrotyrosine (μmol/mg creatine)	15 ± 10	16 ± 15	14 ± 12	12 ± 5ns	15 ± 10	13 ± 11ns
Urinary-F₂ isoprostanes (pg/mg creatine)	750 ± 380	670 ± 444	893 ± 439	863 ± 530ns	943 ± 480	840 ± 540ns
Monocyte superoxide release (nmol/min/mg protein)	1.7 ± 2.3	1.7 ± 1.8	1.2 ± 1.0	1.1 ± 0.9ns	1.3 ± 1.4	1.1 ± 0.8ns

Data expressed as mean ± SD.

p <0.02 compared with baseline.

^†

p < 0.044 compared with placebo.

^‡

p <0.001 compared with baseline and placebo.

^§

p < 0.03 compared with atorvastatin 10 mg/day.

ns = not significant.